A Phase 4 interventional study of Early RASi restart strategy and Usual Care in Acute Kidney Injury, sponsored by University of California, San Francisco. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-08.
Sponsored by University of California, San Francisco · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies in Acute Kidney Injury by University of California, San Francisco — 5 open to participants now, 6 under way, 1 of them phase 3. Acute Kidney Injury · University of California, San Francisco.
Among the 11 studies in Acute Kidney Injury by University of California, San Francisco, this one is the 5th largest by planned enrollment of the 10 interventional ones that give a count, is one of 3 that started in 2026, is one of 3 in phase 4, and was the 11th registered.
1,693 studies on the registry are indexed under Acute Kidney Injury; 392 are open to participants now.
Browse Acute Kidney Injury studies →5 of the 11 studies in Acute Kidney Injury by University of California, San Francisco are open now, in 2 countries. Recruiting first, the newest first:
University of California, San Francisco · Sites in United States
Ages 18+
University of California, San Francisco · Sites in United States, Canada
Ages 18+
University of California, San Francisco · Sites in United States
Ages 18+ · Healthy volunteers
University of California, San Francisco · Sites in United States
Ages 18+ · Healthy volunteers
By country, each count listing its studies:
Of the 229 Acute Kidney Injury studies recruiting now, 161 (70%) set no upper age limit and 35 (15%) stop at 75 or younger; 22 take children under 18; 25 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
First in 2017; this study’s year is marked. 3 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 60 is below the median of 100 across 819 interventional studies indexed under Acute Kidney Injury.
Median enrollment 55 across the 10 interventional studies, 2,000 across the 1 observational. Of the 5 that completed or were terminated, 3 (60%) have results posted.
This tab as a report to print or save as PDF → With an account.
University of California, San Francisco is the lead sponsor of 2,172 studies on the registry; 370 are open to participants now.
Of its 269 completed or terminated interventional studies of FDA-regulated products, 203 (75%) have results posted.
2 of the studies in Acute Kidney Injury by University of California, San Francisco that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04705766University of California, San FranciscoKIDney Injury in Times of COVID-19 (KIDCOV) | 2027-03 |
| NCT07604662University of California, San FranciscoReal-Time Acute Kidney Injury Perioperative Prediction Clinical Trial | 2027-10-15 |
Add all 2 to your calendar (.ics) → With an account.
Among the 11 studies in Acute Kidney Injury by University of California, San Francisco, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The goal of this pilot clinical trial is to learn if early restart of renin-angiotensin system inhibitor (RASi) medications is feasible and well-tolerated in hospitalized patients with acute kidney injury (AKI). Researchers will compare early RASi restart to usual care.
Study participants will restart RASi per study protocol, obtain a lab test in 1-2 weeks if RASi restarted in the hospital and not collected as part of routine care, and answer questions at the 90-day follow-up.
Among at-risk patients with heart failure and chronic kidney disease, use of RASi medications decreases the subsequent risk of adverse events such as cardiovascular death and kidney disease progression. However, RASi treatment is often stopped when AKI is detected in the hospital based on the notion that restoring an intact renin-angiotensin system in the context of hypovolemia or hypotension may be helpful to maintain perfusion to the glomeruli and thus support the glomerular filtration rate.
In observational studies, restart of RASi medications among at-risk patients after AKI has been associated with decreased subsequent rates of mortality, cardiovascular events, and kidney disease progression. However, there is no rigorous evidence from randomized trials to guide optimal strategy of RASi restart after AKI.
This is a pilot trial among hospitalized patients with AKI whose RASi were held to investigate the feasibility and tolerability of a strategy of early RASi restart (n=30) compared to usual care (n=30). This pilot trial will provide valuable data critical to inform the design of a larger definitive trial.
The study hypothesis is that the strategy of early RASi restart after AKI is feasible and well-tolerated. This pilot trial will inform the design of a larger definitive trial to determine whether early RASi restart can increase rates of RASi use at 90 days compared to usual care.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RASi restart will be deferred to the study participant's providers.
Drug: Usual Care
The early restart strategy is to resume RASi as soon as the serum creatinine (SCr) downtrends by ≥0.3mg/dL from peak. In addition, the following criteria must be met: most recent potassium ≤5mEq/L, SCr-based eGFR reported as ≥15 mL/min/1.73m2, and average systolic blood pressure≥120mmHg 12 hours prior to restart. If the study participant is discharged from the hospital before the RASi restart criteria are met, management of RASi restart would be deferred to the discretion of longitudinal outpatient healthcare team.
Drug: Early RASi restart strategy
The early restart strategy is to resume RASi as soon as the serum creatinine (SCr) downtrends by ≥0.3mg/dL from peak. In addition, the following criteria must be met: most recent potassium ≤5mEq/L, CKD-EPI SCr-based eGFR reported as ≥15 mL/min/1.73m2, and average SBP ≥120mmHg 12 hours prior to restart. If the study participant is discharged from the hospital before the RASi restart criteria are met, management of RASi restart would be deferred to the discretion of longitudinal outpatient healthcare team.
Also known as: renin-angiotensin system inhibitors
RASi restart will be deferred to the study participant's providers.
Feasibility- RASi use separation
Proportion of patients in the early RASi restart arm and the usual care arm who restart RASi within 72 hours of SCr downtrending by ≥0.3mg/dL from peak SCr and at hospital discharge
Time frame: From date of enrollment until date of hospital discharge or up to 90 days if remains in the hospital
Tolerability- 90 day follow up completion
Proportion of participants who complete 90 day follow up
Time frame: Up to 90 days
Tolerability- Lab evaluation post RASi
Proportion with potassium and SCr evaluations within 1-2 weeks of RASi restart
Time frame: Up to 2 weeks post hospital discharge or 90 days if patient remains in the hospital
Tolerability- SCr evaluation after hospital discharge
Proportion with SCr evaluation after hospital discharge
Time frame: Up to 90 days
Tolerability- Proteinuria evaluation
Proportion with proteinuria evaluation after hospital discharge
Time frame: Up to 90 days
Screening-to-recruitment ratio
Number of patients screened divided by the number of patients enrolled
Time frame: Total study duration, anticipated 2.5 years, up to 4 years total
Adverse events
Total number of adverse events and number of adverse events attributable to study intervention. Adverse events include: hyperkalemia (\>5.5mEq/L and \>6mEq/L), recurrent AKI (minor (30-\<50% decline) versus major (\>=50% decline) in eGFR), symptomatic hypotension or hypertension, emergency room visits, hospitalizations, increase index hospital length of stay
Time frame: Up to 90 days
90 day RASi use
Proportion with RASi use at 90 days
Time frame: Up to 90 days
Cumulative RASi exposure
Number of days with RASi use
Time frame: Up to 90 days
Days to RASi restart
Days to RASi restart from day of peak SCr
Time frame: Up to 90 days
Plan to share: Yes — Individual participant data collected after deidentification
Supporting information: Study protocol
No publications or documents are linked to this record.
Started Sep 2026 (actual). Primary completion is estimated for Mar 2029, 30 months after the start.
Of 46 non-industry phase 4 interventional studies under Acute Kidney Injury, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 57. This study's planned 30 months is close to that.
Counting every sponsor, half of 47 studies reached it within 30 months; a quarter within 14 and three quarters within 57.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of California, San Francisco →